Natalia V. Myakova

Prof. Natalia V. Myakova


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
BBBirgit Burkhardt
Birgit Burkhardt
MTMary Taj
Mary Taj
NGNathalie Garnier
Nathalie Garnier
VMVeronique Minard-Colin
Veronique Minard-Colin
VHVolkan Hazar
Volkan Hazar
Marta PillonMarta Pillon
Marta Pillon
Despite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.

Verified
Journal Article
Open access
PDF file
ASAlexandra Semchenkova
Alexandra Semchenkova
EMEkaterina Mikhailova
Ekaterina Mikhailova
AKAlexander Y Komkov
Alexander Y Komkov
MGMarina Gaskova
Marina Gaskova
RARuslan Abasov
Ruslan Abasov
APAlexander popov
Alexander popov
We report incidence and deep molecular characteristics of lineage switch in 182 pediatric patients affected by B-cell precursor acute lymphoblastic leukemia (BCP-ALL), who were treated with blinatumomab. We documented six cases of lineage switch that occurred after or during blinatumomab exposure. Therefore, lineage conversion was found in 17.4% of all resistance cases (4/27) and 3.2% of relapses (2/63). Half of patients switched completely from BCP-ALL to CD19-negative acute myeloid leukemia, others retained CD19-positive B-blasts and acquired an additional CD19-negative blast population: myeloid or unclassifiable. Five patients had KMT2A gene rearrangements; one had TCF3::ZNF384 translocation. The presented cases showed consistency of gene rearrangements and fusion transcripts across initially diagnosed leukemia and lineage switch. In two of six patients, the clonal architecture assessed by IG/TR gene rearrangements was stable, while in others, loss of clones or gain of new clones was noted. KMT2A-r patients demonstrated very few additional mutations, while in the TCF3::ZNF384 case, lineage switch was accompanied by a large set of additional mutations. The immunophenotype of an existing leukemia sometimes changes via different mechanisms and with different additional molecular changes. Careful investigation of all BM compartments together with all molecular –minimal residual disease studies can lead to reliable identification of lineage switch.

5 November 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EMEkaterina Mikhailova
Ekaterina Mikhailova
OIOlga Illarionova
Olga Illarionova
AKAlexander Y Komkov
Alexander Y Komkov
EZElena Zerkalenkova
Elena Zerkalenkova
IMIlgar Z. Mamedov
Ilgar Z. Mamedov
APAlexander popov
Alexander popov
We aimed to develop an antibody panel and data analysis algorithm for multicolor flow cytometry (MFC), which is a reliable method for minimal residual disease (MRD) detection in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) treated with CD19-directed therapy. The development of the approach, which was adapted for the case of possible CD19 loss, was based on the additional B-lineage marker expression data obtained from a study of primary BCP-ALL patients, an analysis of the immunophenotypic changes that occur during blinatumomab or CAR-T therapy, and an analysis of very early CD19-negative normal BCPs. We have developed a single-tube 11-color panel for MFC-MRD detection. CD22- and iCD79a-based primary B-lineage gating (preferably consecutive) was recommended. Based on patterns of antigen expression changes and the relative expansion of normal CD19-negative BCPs, guidelines for MFC data analysis and interpretation were established. The suggested approach was tested in comparison with the molecular techniques: IG/TR gene rearrangement detection by next-generation sequencing (NGS) and RQ-PCR for fusion-gene transcripts (FGTs). Qualitative concordance rates of 82.8% and 89.8% were obtained for NGS-MRD and FGT-MRD results, respectively. We have developed a sensitive and reliable approach that allows MFC-MRD monitoring after CD19-directed treatment, even in the case of possible CD19 loss.

31 March 2016 in Oncohematology
Verified
Journal Article
Open access
PDF file
NMNatalia V. Myakova
Natalia V. Myakova
DED. A. Evstratov
D. A. Evstratov
DAD. S. Abramov
D. S. Abramov
DKD. M. Konovalov
D. M. Konovalov
AПArray В. Пшонкин
Array В. Пшонкин
DLD. V. Litvinov
D. V. Litvinov
Despite significant advances in the treatment of lymphomas in children remain a small proportion of patients with refractory or recurrent disease. An effective approach to the treatment of such patients – not only is the second line chemotherapy, but the use of the new targeted therapies. An example of this approach is the use of brentuximab vedotin (antibody-drug conjugate directed to the CD30) in relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma. Literature review and own experience of using this drug in children are describes in this article.

23 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
APAlexander popov
Alexander popov
GHGünter Henze
Günter Henze
JRJulia Roumiantseva
Julia Roumiantseva
OBOleh Bydanov
Oleh Bydanov
MBMikhail Belevtsev
Mikhail Belevtsev
AKAlexander Karachunskiy
Alexander Karachunskiy
This report presents the results of the assessment of MRD response by multicolor flow cytometry (MFC) with regard to the randomized use of pegylated asparaginase (PEG). In this study, PEG was randomly administered at a dose of 1000 U/m2 on day 3 of induction therapy in children with B-lineage ALL. Methods. Conventional induction therapy consisted of dexamethasone, vincristine, and daunorubicin. MRD data was available in 502 patients who were randomized at the start of induction therapy, standard-risk (SR) patients into three (conventional induction without PEG, induction with additional PEG and with PEG but without daunorubicin) and intermediate-risk (ImR) patients into two groups (with additional PEG and without PEG). Results. The single administration of PEG resulted in a significantly higher proportion of rapid responders, in SR patients even when no anthracyclines were used for induction. In the SR group, the event-free survival of the MFC-MRD fast responders was similar in the PEG− and PEG+ arms (92.0 ± 3.1% vs. 96.2 ± 1.5%, respectively), and the same unfavorable trend was observed for MFC-MRD slow responders (57.5 ± 12.3% vs. 66.7 ± 15.7%, respectively). Results were similar in ImR patients: (94.3 ± 3.2% vs. 95.1 ± 2.4%, for fast responders and 63.3 ± 7.6% vs. 78.1 ± 7.9%, for slow responders in PEG− and PEG+ arms, respectively). However, there is a large difference between the proportion of MFC-MRD slow responders in the PEG− and PEG+ groups (18.3% vs. 5.2% for the SR group and 44.2% vs. 25.0% for the ImR group). Conclusions. Therefore, early use of PEG-ASP not only leads to an accelerated reduction of blasts, but also to an excellent outcome in a significantly larger proportion of patients in both risk groups.

19 December 2015 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
SOS. S. Ozerov
S. S. Ozerov
AMA. V. Melnikov
A. V. Melnikov
ASA. E. Samarin
A. E. Samarin
GTG. V. Tereshchenko
G. V. Tereshchenko
EKE. V. Kumirova
E. V. Kumirova
МВМякова Наталья Валерьевна
Мякова Наталья Валерьевна
Ommaya reservoir is a convenient and reliable port for intraventricular injection of chemotherapeutic drugs in patients with oncohematological and neuro-oncological diseases. A total of 45 Ommaya reservoirs were implanted in 45 patients at the Federal Research Center of Pediatric Hematology, Oncology, and Immunology named after Dmitry Rogachev (Moscow) in 2012-2015. Because of small ventricles in most cases Ommaya reservoirs were implanted by stereotactic procedure. Intraventricular injection of methotrexate supported a high and stable concentration of the drug in the cerebrospinal fluid and proved to be a good alternative to intrathecal administration. In hydrocephalus Ommaya reservoir could be combined with pressure-regulated ventriculoperitoneal shunt, this providing a high concentration of methotrexate in the cerebrospinal fluid, safe for the patient.